KR101703352B1 - Artemisia extract - Google Patents

Abstract

The present invention relates to a lobule extract obtained by extracting with alcohol having 4 carbon atoms and a lecithin extract in which blood coagulation inhibitor is completely removed even if a separate elimination step is not added as compared with the conventional art.

Artemisia, Artemisia extract, alcohol,

Description

{ARTEMISIA EXTRACT}

Artemisia mongolica, A. asiatica, A. princeps var. Orientalis, A. argyi, A. montana, etc.) is a perennial herb belonging to Asteraceae and has been used as an agent for the treatment of gynecological diseases, gynecological diseases and diarrhea And the flavanoids such as yupatilin and oriental ostidine were also identified in the Korean Pharmacopoeia Specification of Chinese medicine (herbal medicine). Also, the leaves and young stems of the mugwort were also called "叶葉, Artemisiae argyi Herb). Among them, eupatilin, which is a flavonoid component, has been known to have an antiallergic effect (Japanese Patent Laid-Open Publication No. 59-155314), and its utility as a therapeutic agent for gastrointestinal diseases has recently been disclosed in Korea. (Korean Patent Registration No. 127777) In addition, another flavonoid component, jaseocidin, is also registered as a patent that can be used as a therapeutic agent for the same gastrointestinal diseases. (Korean Patent Registration No. 181751)

On the other hand, Korean Patent Registration No. 181751 discloses that the antagonistic effect of mugwort extract itself is more excellent than the antitumor effect of refined mugwort-infused oil tilline or oriental osidine, Korean Patent Laid-Open Publication No. 2006-0002639 discloses that the blood coagulation inhibitory component contained in mugwort, that is, coumarin, especially Dicoumarol, is contained in the extraction process.

As described in the prior art, decumarol is a component that can be used with great care even though it can be used for medical purposes because it can dramatically reduce the platelet count even with small doses and has reported hepatotoxicity. In addition, patients with gastritis or gastric ulcer are more likely to have gastrointestinal bleeding due to gastrointestinal damage. In the above-mentioned prior art, it is stated that the alcohol or alcohol aqueous solution extract according to the conventional Korean Patent Registration No. 181751 does not easily remove this component. As a method for removing this component, 1) (Step 1); 2) adding an alkali solution to the extract obtained in step 1 and reacting at 80 ° C for 1 hour or more (step 2); 3) adding an acidic solution to the extract obtained in step 2 (Step 3); and 4) lyophilizing the extract obtained in step 3 after concentration under reduced pressure (step 4). That is, it can be seen that the dicumarol component can be easily removed by including alkali treatment of steps 2 and 3 and its neutralization process in the prior art. Unlike the conventional extraction method, in the present invention, (C4), it does not contain decumarol, which is a blood coagulation inhibiting component, even without a separate additional removal step, thereby completing the present invention.

It is an object of the present invention to provide a lyocyte extract which does not contain a coagulant component, which is a blood coagulation component, even though a separate removal step is not performed.

The present invention relates to a method of extracting and extracting a leaf from an extract of a leaf, which is extracted and concentrated with an alcohol having 4 carbon atoms, such as 2-butanol (isobutanol), 1-butanol (n-butanol), 2-methyl- The present invention is characterized in that it does not contain decumaryl, even if it does not contain a blood coagulation inhibitor, that is, a separate process for removing the decumarol in the extraction and concentration process. The lobes used in the present invention are Artemisia A. montana, A. mongolica, and the Korean Pharmacopoeia (herbal medicines) Specification, for example, A. argini, A. argini, A. princeps var. orientalis, A. asiatica. The present invention relates to a method of extracting alcohol from a mixture of an alcohol having 4 carbon atoms and a conventional method for extracting medicines, that is, The leaching solution is immersed in the solution for a sufficient period of time after adding the solvent to the solution of the leaching solution, After appropriate filtration, the filtrate is concentrated under reduced pressure to obtain an extract.

Through the present invention, it is possible to secure a lyophilized extract which does not contain a blood coagulation inhibitor even if it does not include a separate additional removal step.

≪ Example 1 >

To 300 g of Artemisia princeps Pamp. Var. Orientalis, 2500 mL of 2-butanol is added, and the mixture is immersed for about 24 hours. The mixture is heated to 80 캜 and vacuum filtered. To the residue was added 1300 mL of 2-butanol, followed by immersion extraction for about 24 hours, filtering through the same process, and combining with the previous filtrate. This was centrifuged and filtered to obtain 15.7 g of Mugwort extract. (Yield about 20: 1)

≪ Example 2 >

To 300 g of Artemisia princeps Pamp. Var. Orientalis, 2500 mL of 1-butanol is added and the mixture is immersed for about 24 hours. The mixture is heated to 80 캜 and vacuum filtered. 1-butanol (1300 mL) was added to the residue, and the mixture was immersed for about 24 hours, filtered through the same process, and then combined with the previous filtrate. This was centrifuged and filtered to obtain 15.5 g of Mugwort extract. (Yield about 20: 1)

≪ Example 3 >

To 300 g of Artemisia princeps Pamp. Var. Orientalis, 2500 mL of 2-methyl-1-propanol is added, and the mixture is immersed and extracted for about 24 hours. To the residue was added 1300 mL of 2-methyl-1-propanol, followed by immersion extraction for about 24 hours, filtration through the same process, and combining with the previous filtrate. This was centrifuged and filtered to obtain 15.5 g of Mugwort extract. (Yield about 20: 1)

EXPERIMENTAL EXAMPLE 1 [0041] The contents of the milk tiller, the postural oocidine and the dicumarol

Among the extracts according to the above examples, the content of the drug efficacy indicator oil substances, that is, the content of dipyrrhin, the positional osteidine and the blood coagulation inhibiting component, is as follows.

Example
Ingredient content Yupatiline Posture osidine Dicumarol Example 1 1.95% 0.99% Non-detection Example 2 2.92% 1.48% Non-detection Example 3 0.60% 0.32% Non-detection

In other words, it was found that no dicumarol, which is a blood coagulation inhibiting component, was contained in the solution containing ephedrine and postural oocyte, which are known as active ingredients.

Figure 1 is a chromatogram of a standard product of Dicumarol.

2 is a chromatogram of the 2-butanol extract of the leaf of Example 1;

3 is a chromatogram of the 1-butanol extract of the leaf of Example 2;

4 is a chromatogram of the 2-methyl-1-propanol extract of the leaf of Example 3.

FIG. 5 is a chromatogram obtained by overlapping and enlarging FIGS. 1 to 4. FIG.

Claims (4)

delete delete delete A step of extracting leaflets with an alcohol having 4 carbon atoms selected from the group consisting of 2-butanol, 1-butanol and 2-methyl-1-propanol; And A method for producing a lyophilized extract, which comprises a step of filtering and concentrating the extract, wherein the lyocarol-free lyocyte extract is free from a step of removing a decumarole.

Images